Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC5 | P28715 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | NPEPPS | P55786 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.32 |
| ▸ | USP1 | O94782 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29326204 | 0.89 | ERCC5 (0.40) | ERCC5FEN1NPEPPSADRA1B | |
| SCHEMBL27380824 | 0.85 | KDM4E (0.34) | ERCC5FEN1CYP11B1CYP11B2NPEPPS | |
| SCHEMBL27192316 | 0.85 | CYP1A1 (0.44) | ERCC5FEN1CYP11B1CYP11B2NPEPPS | |
| SCHEMBL27377359 | 0.85 | CYP1A1 (0.44) | ERCC5FEN1CYP11B1CYP11B2NPEPPS | |
| SCHEMBL27377355 | 0.85 | HAVCR2 (0.38) | ERCC5FEN1CYP11B1CYP11B2NPEPPS | |
| SCHEMBL27377733 | 0.83 | NPEPPS (0.38) | FEN1CYP11B1CYP11B2NPEPPS | |
| SCHEMBL27192298 | 0.83 | SLC22A12 (0.38) | ERCC5FEN1CYP11B1CYP11B2NPEPPS | |
| SCHEMBL27377344 | 0.82 | ERCC5 (0.54) | ERCC5FEN1CYP11B1CYP11B2NPEPPS | |
| SCHEMBL27377352 | 0.82 | ERCC5 (0.36) | ERCC5FEN1CYP11B1CYP11B2NPEPPS | |
| SCHEMBL27377591 | 0.81 | ERCC5 (0.38) | ERCC5FEN1CYP11B1CYP11B2NPEPPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2024-07-18 | — | — | US | disclosed |
| WO-2024031089-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239807-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | ERCC5 2042/4885FEN1 1012/4885CYP11B1 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.